Abstract:Tumorogenesis is characterized by the unregulated proliferation of cells, which is the consequence of dysregulated cell division mechanisms. To ensure the rapid multiplication and invasion, tumor tend to create unique tumor microenvironment (TME) benefiting its own progression. As abnormal component in the body, figuring out how to escape from the supervision and attack of immune system is the key of tumor survival. Angiogenesis, which is mainly triggered by the stimulation of vascular endothelial growth factor (VEGF), is one of its solutions. Characterized by hypoxia, most type of tumor cells significantly upregulate VEGF, which stimulates active construction of tumor neovascularization. [1][2][3] However, the newly-formed tumor blood vessels show series of abnormalities, including increased luminal resistance, increased endothelial permeability and limited blood flow caused by defects in structure. [4] The features above are beneficial to the tumor growth and metastasis, as well as immune evasion, inducing resistance to immunotherapy. It was reported that anti-angiogenesis therapy has been seen as a promising strategy to enhance tumor immune response, which contributes to improve immunosuppressive TME and helps with anti-tumor effects by immune system. [5][6][7] The relation between angiogenesis and immune response was revealed in gene and transcriptomic level. Kurmyshkina et al. focused on the difference of transcriptomic landscapes between early-stage invasive cervical carcinoma (CeCa) and cervical intraepithelial neoplastic lesions (CIN). The authors found that innate immune pathways in early-stage CeCa were significantly upregulated in response to the infection of human papillomavirus, compared with CIN as precursor lesions. The tumors with active immune infiltration showed a more differentiated phenotype, while the ones with increased expression of genes associated with angiogenesis were related to exacerbation of de-differentiation and epithelial-to-mesenchymal transition. As reported, anti-angiogenesis therapy was expected to improve immune evasion and enhance immune infiltration. Shafqat et al. summarized previous studies which focused on tumor angiogenesis and coagulation exert suppressive effects on anti-tumor immune response. Both of them mediates the impacts above through specific mechanisms ultimately leading to the reprogramming of TME. Whether the usage of anti-angiogenic therapies to achieve vascular normalization and ACEi/ARBs to achieve stromal normalization targeting angiogenesis, or anticoagulants targeting coagulation, showed similar result of limit tumor progression and transform TME to favor immune response against tumors. Also, they both demonstrated the efficacy of enhance immunotherapy while combining with ICIs, despite the heterogeneity of tumor types still needs to be considered in the conjunction. It is natural to associate angiogenesis with prognosis since its influence on tumor invasion and progression. Li et al. developed an advanced machine learning model to evaluate the prognosis and therapy response of breast cancer based on several genes related to vascular mimicry (VM), the performance of which continuously exceeds that of traditional ones. The tumor group received higher VM scores than the normal group. The high-risk group showed higher level of tumor mutation burden (TMB) and higher mutation rate of tumor suppressor genes, and higher level of immune escape suggesting poor response to immunotherapy at the same time. Meanwhile, the low-risk group appeared more favorable response to immune checkpoint blockage. Eventually, the authors identified several promising chemotherapy drugs to which was VM related genes sensitive.To summarize, the studies above introduce some latest advances in the roles of angiogenesis and immune response in TME of solid tumors, and hopefully contribute to the further explorations of immunotherapy enhancer. We would like to acknowledge the invaluable support of all authors, reviewers and the editor team during the topic preparation process. We are looking forward to significant breakthroughs in the approach of sensitizing immunotherapy through anti-angiogenesis agents to emerge soon.

Direct and indirect regulation of the tumor immune microenvironment by VEGF

Abstract 365: Autocrine Vascular Endothelial Growth Factor Signaling Mediates Survival and Chemoresistance of Human Colorectal Cancer Cells

Targeting VEGF/VEGFR to Modulate Antitumor Immunity

Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

Anti-angiogenic Active Immunotherapy: a New Approach to Cancer Treatment

Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade

Editorial: Community series in the role of angiogenesis and immune response in tumor microenvironment of solid tumor, volume III

The Impact of VEGF on Cancer Metastasis and Systemic Disease.

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Clinical applications of VEGF-trap (aflibercept) in cancer treatment.

Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy

A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models

Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?

Tumor Angiogenesis and Signal Transduction Via Vascular Endothelial Growth Factor Receptor

Vascular endothelial growth factor inhibitors promote antitumor responses via tumor microenvironment immunosuppression in advanced colorectal cancer

VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment

Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies